NCT03335839View on ClinicalTrials.gov

Adjunctive, Low-dose tPA in Primary PCI for STEMI

PHASE3CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

September 17, 2024

Study Completion Date

February 12, 2025

Conditions
Myocardial InfarctionPercutaneous Coronary Intervention
Interventions
DRUG

tissue plasminogen activator

Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.

OTHER

Saline

Placebo

Trial Locations (3)

T2N 4Z6

University of Calgary - Foothills Medical Centre, Calgary

T6G 2B7

University of Alberta - Mazankowski Alberta Heart Insitute, Edmonton

L8L2X2

Hamilton General Hospital, Hamilton

Sponsors
All Listed Sponsors
collaborator

Heart and Stroke Foundation of Canada

OTHER

lead

Population Health Research Institute

OTHER

NCT03335839 - Adjunctive, Low-dose tPA in Primary PCI for STEMI | Biotech Hunter | Biotech Hunter